BioSpace News Archive

PREXA SANTÉ announced positive top-line results from a human clinical trial of Product-118, the company’s proprietary combination medical device/drug treatment for COVID-19.

TeamedOn International, Inc. and Applied Genetic Technologies Corporation announced a licensing agreement to advance gene therapy to treat X-linked retinoschisis, an inherited disease that causes loss of vision due to degeneration of the retina in males.

Tiziana Life Sciences plc, announced that its former subsidiary, Accustem Sciences Limited, intends to file a listing application with the Nasdaq Stock Market shortly after completion of the distribution of shares in Accustem to Tiziana Life Sciences plc shareholders.

Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health” or the “Company”), and Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, today announced statistically significant topline data from the first Phase 3 trial (GOBI trial)

LumiraDx announced today that it has received a reissued Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for LumiraDx SARS-CoV-2 RNA STAR Complete, a rapid, nucleic acid amplification method for high sensitivity, high throughput COVID-19 testing.

Theseus Pharmaceuticals, a biotechnology company shaping the future of targeted oncology by developing best-in-class, pan-variant kinase inhibitors, emerged from stealth today announcing the close of a $100 million Series B financing led by Foresite Capital.

Peptilogics, a biotechnology platform company leveraging computational design to discover novel peptide therapeutics, today announced the completion of a Phase 1 clinical trial for its lead compound PLG0206

BIOCORP, a French company specialized in the design, development and manufacturing of innovative medical devices, and Roche Diabetes Care France, a reference company in the support of patients with diabetes, announce the launch in France of Mallya, a medical device available in pharmacies.

First-in-Human Clinical Trial of EpiEndo’s Lead Compound, EP395, for Chronic Inflammatory Airway Diseases Commences at the Medicines Evaluation Unit in Manchester, UK

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announce the decision to continue the recruitment of patients in the phase III clinical trial of brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer’s type.